Business
Novocure Announces Agenda for Virtual Research and Development Day
Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development ST. HELIER,
About this update from Novocure Limited
[{"type":"text","content":"\nEvent will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development\n\n ST. HELIER, Jersey--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EST on Thursday, November 12, 2020. The event will review two decades of Tumor Treating Fields research on and introduce exciting new directions of ongoing research and development across the global scientific community. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields. For live access to the event, please register using this link.\n\n“With readouts from key clinical trials in multiple indications anticipated over the next few years, we felt it was important to review the extensive body of research conducted over the past two decades that give us confidence and to introduce areas of ongoing research intended to identify optimal use of Tumor Treating Fields and to improve the predictive value of scientific evidence generated,” stated William Doyle, Novocure’s Executive Chairman. “We are also excited to highlight growing interest in Tumor Treating Fields from across the global scientific community as we advance our mission to extend survival in some of the most aggressive forms of cancer.”\n\nThe event will feature six leaders from Novocure’s research and development teams and five external key opinion leaders actively engaged in Tumor Treating Fields research programs. The agenda for Novocure’s virtual research and development day is as follows:\n\n7:30 a.m. EST\nWelcome and introductory remarks\nSpeaker: William Doyle, Novocure’s Executive Chairman\n\n7:40 a.m. EST\nTumor Treating Fields’ mechanism of action\nSpeaker: Dr. Uri Weinberg, Novocure’s Chief Science Officer\n\n7:45 a.m. EST\nApplying basic biology to address critical unmet needs\nSpeakers: Dr. Moshe Giladi, Novocure’s Director of Preclinical Research and Dr. Carsten Hagemann, University Hospital Würzburg\n\n8:00 a.m. EST\nLeveraging physics to address critical unmet needs\nSpeakers: Dr. Ze’ev Bomzon, Novocure’s Director of Science and Dr. Matthew Ballo, West Cancer Center & Research Institu...